Ramsay Healthcare – FY18

Ramsay Healthcare reported FY18 results in-line with market consensus, however, the FY19 guidance was below expectations.

Underlying earnings increased 7% in FY18 and that growth rate is likely to slip to 4 – 5% in FY19. With the stock on a forward yield of 2.7% we see further downside risk to the share price in the short-term.

You're not a member!  Trial today!

RHC is a high quality business and we’ll be watching for the next Algo Engine buy signal.

Material earnings benefits from new hospital  projects are expected in the coming years; we see both Healthscope and Ramsay Healthcare as long-term value plays with a defensive yield.

Buy Healthscope today and remain patient for the entry condition into Ramsay.

 

Investor Signals Pty Ltd ABN 44 143 555 453 is a Corporate Authorised Representative CAR No. 439411 of Advisor Plus Pty Ltd AFSL 474520
© 2020 Investor Signals